Usefulness of Recombinant Human Erythropoietin (KRN5702) in the Treatment of Anemia Associated with Rheumatoid Arthritis.

概要

論文の詳細を見る
Therapeutic effects of recombinant human erythropoietin (rHuEPO) in the treatment of anemia associated with rheumatoid arthritis (RA) were evaluated by multi center cooperative trial. Thirty-nine patients with RA received rHuEPO intravenously at 200IU/kg once a week (Group 1) or 100IU/kg three time a week (Group 2) for 8 weeks. The mean value of hematocrit (Ht) was 25.7% in Group 1 and 27.4% in Group 2 before the treatment, and increased to 29.6% and 32.1% respectively after 8 weeks. The treatment resulted in significant improvement of Ht in both groups. rHuEPO was more effective in higher serum iron group (>29μg dl) and/or lower plasma EPO concentration group ( ≤ 30mIU/ml) in the base line. The effective improvement on anemia of "effective" or more was 50 and 65% in Groups 1 and 2, respectively. The global improvement of "improvement" or more was 32% in Group 1 and 55% in Group 2. Side effects included hypertension in 2 of the 39 patients, presumably as a result of the rapid rise of Ht value. There were no other findings to be marked. In conclusion, patients with RA showed excellent hemoglobin responses to rHuEPO, although a meaningful change in rheumatic manifestation was not seen.
日本炎症・再生医学会の論文